uniQure (NASDAQ:QURE) Insider Kylie O’keefe Sells 15,936 Shares

uniQure N.V. (NASDAQ:QURE) insider Kylie O’keefe sold 15,936 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $431,228.16. Following the completion of the sale, the insider directly owned 108,864 shares of the company’s stock, valued at approximately $2,945,859.84. The trade was a 12.77% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

uniQure Stock Up 2.8%

Shares of NASDAQ QURE traded up $0.75 during trading hours on Friday, hitting $27.57. The stock had a trading volume of 835,627 shares, compared to its average volume of 2,601,234. The company has a market capitalization of $1.74 billion, a P/E ratio of -7.92 and a beta of 0.98. The firm’s 50-day moving average price is $22.31 and its two-hundred day moving average price is $21.76. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. Analysts anticipate that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Chardan Capital raised their target price on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Barclays cut their target price on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a research report on Monday, March 23rd. TD Cowen restated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Stifel Nicolaus set a $28.00 price target on uniQure in a research report on Tuesday, May 5th. Finally, Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $12.00 to $35.00 in a research report on Wednesday, March 11th. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $42.83.

Institutional Investors Weigh In On uniQure

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Militia Capital Management LLC acquired a new stake in shares of uniQure in the first quarter worth $1,540,000. Flax Pond Capital LLC grew its stake in shares of uniQure by 3.8% in the first quarter. Flax Pond Capital LLC now owns 152,031 shares of the biotechnology company’s stock worth $2,486,000 after acquiring an additional 5,533 shares during the last quarter. Stempoint Capital LP grew its stake in shares of uniQure by 79.5% in the first quarter. Stempoint Capital LP now owns 78,066 shares of the biotechnology company’s stock worth $1,276,000 after acquiring an additional 34,581 shares during the last quarter. Irenic Capital Management LP acquired a new stake in shares of uniQure in the first quarter worth $1,635,000. Finally, Readystate Asset Management LP grew its stake in shares of uniQure by 39.6% in the first quarter. Readystate Asset Management LP now owns 504,702 shares of the biotechnology company’s stock worth $8,252,000 after acquiring an additional 143,142 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.